'More Positive Conversations' global survey
The 'More Positive Conversations' survey was conducted online and via telephone interviews by Harris Interactive on behalf of AstraZeneca. The survey involved 1,062 physicians and patients from France, Germany, Italy, the United Kingdom and the US.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.
Arimidex (anastrozole) is a trademark, the property of the AstraZeneca
group of companies.
1. The ATAC Trialist Group -Effect of anastrozole and tamoxifen as
adjuvant treatment for early-stage breast cancer; 100 month analysis of
the ATAC trial -published online, Lancet Oncology Saturday 15 December
2. Forbes J, on behalf on the ATAC Trialist's Group. ATAC: 100 month
median follow-up shows continued superior efficacy and no excess
fracture risk for anastrozole compared with tamoxifen after treatment
completion. Abstract no 41. San Antonio Breast Cancer Symposium 2007.
3. Parkin, D.M., E. Laara, and C.S. Muir, Estimates of the worldwide
frequency of sixteen major cancers in 1980. Int J Cancer, 1988. 41(2):
4. Breastcancer.org. What role to hormones play in breast cancer
treatment. Available from
Copyright©2007 PR Newswire.
All rights reserved